ClinicalTrials.gg
RecruitingNCT06780501REFINEUpdated Jan 17, 2025

Neuropsychiatric Research Databases for People With Intellectual Disabilities and Epilepsy (REFINE)

An observational study in Epilepsy, Intellectual Disability and Learning Disability, sponsored by University of Plymouth. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by University of Plymouth · Observational

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

This study consists of two parts:

Part One: De-identified Database

The goal of this part is to establish a research database containing de-identified data about People with Intellectual Disabilities (PwID) and epilepsy, collected from three NHS sites across England and Wales. Researchers will gather information from participants' medical records, including clinical details, epilepsy history, and medications, and will enter this data into a secure database where all identifying details are removed. This part of the study aims to determine whether it's possible to identify eligible participants, collect complete datasets for each participant, and identify any issues that may affect the quantity and quality of data. These findings will help inform a potential future study that could involve 20 or more sites.

Part Two: Research Register

The goal of this part is to create a research register of individuals with PwID and epilepsy. Participants will be approached and asked for their consent to collect their personal and clinical data, which will help identify those willing to take part in future ethically approved research projects. As in Part One, researchers will collect data from medical records. Participants who consent to be included in the register may be contacted by external researchers for future studies. The aim is to facilitate national collaboration by enabling data sharing between research projects, thereby improving the ability to answer more questions and enhance patient care. This part of the study will test whether it's possible to determine screening and recruitment rates at each site, develop and evaluate recruitment processes, and assess how researchers leading other approved studies can obtain permission to use the register. Additionally, it will evaluate whether it's possible to collect a complete dataset for each participant.

02

Conditions studied

  • Epilepsy
  • Intellectual Disability
  • Learning Disability
03

In context

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 422 are open to participants now.

This study's planned enrollment of 600 is above the median of 112 across 540 observational studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

University of Plymouth is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with a clinical diagnosis of an Intellectual Disability (ID) and epilepsy at participating sites.

Eligibility criteria

The de-identified database:

Inclusion Criteria:

  • Clinical diagnosis of ID in medical records.
  • Clinical diagnosis of epilepsy in medical records.
  • Patient is over the age of 18 years old.
  • Under the current care of specialist ID or epilepsy services at one of the three participating NHS Trusts.

Exclusion Criteria:

  • Other neurodevelopmental disorders without ID.
  • Patient is recorded on the National Data Opt-out as not wishing their data to be used for research/audit.

The research register:

Inclusion Criteria:

  • Clinical diagnosis of ID in medical records.
  • Clinical diagnosis of epilepsy in medical records.
  • Under the current care of specialist ID or epilepsy services at one of the three participating NHS Trusts.
  • Between the ages of 18 and 30 at the time of consent.
  • Participant has the capacity to be able to provide consent for themselves, or a personal consultee is able to provide an opinion on the views and feelings of the potential participant.
  • Patients (or personal consultee) must be able to communicate in English (or Welsh in Welsh site).

Exclusion Criteria:

  • Other neurodevelopmental disorders without ID.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
600 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. The set up of a research database consisting of de-identified data focused on People with Intellectual Disabilities (PwID) and epilepsy at three UK NHS sites across England and Wales.

    De-identified database

    Time frame: End of study (May 2025)

  2. The development of a research register of PwID and epilepsy. Participants will consent to the collection of their personal/clinical data, which will enable the identification of patients willing to take part in other ethically approved research projects.

    Research register

    Time frame: End of study (May 2025)

Secondary outcomes

  1. Numbers of eligible patients identified at each site for data collection (De-identified database).

    Feasibility objective

    Time frame: End of study (May 2025)

  2. Completeness of clinical data collected (De-identified database)

    Feasibility objective

    Time frame: End of study (May 2025)

  3. Feedback collected from sites about any issues around identifying patients and locating the data required (De-identified database).

    Feasibility objective

    Time frame: End of study (May 2025)

  4. Screening and recruitment rates at each site (Research register).

    Feasibility objective

    Time frame: End of study (May 2025)

  5. Successful recruitment process in place at each site (Research register).

    Feasibility objective

    Time frame: End of study (May 2025)

  6. Set up of a formal process including the REFINE Study Oversight Committee to review requests for access to the participant register (Research register).

    Feasibility objective

    Time frame: End of study (May 2025)

  7. Completeness of clinical data collected (Research register).

    Feasibility objective

    Time frame: End of study (May 2025)

07

Study locations

2 of 3 sites recruiting
  • Cornwall Partnership NHS Foundation Trust
    Bodmin, United Kingdom
    Recruiting
    • Sarah Lennard · Contact
    • Sarah Lennard · Principal investigator
  • Royal Free London Hospitals NHS Trust
    London, United Kingdom
    Not yet recruiting
    • Heather Angus-Leppan · Contact
    • Heather Angus-Leppan · Principal investigator
  • Swansea Bay University Health Board
    Swansea, United Kingdom
    Recruiting
    • Lance Watkins · Contact
    • Lance Watkins · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06780501
Lead sponsor
University of Plymouth
Collaborators
Peninsula Clinical Trials Unit
Responsible party
Professor Rohit Shankar (Professor in Neuropsychiatry, University of Plymouth) — Principal investigator
First posted
Jan 17, 2025
Start date
Sep 12, 2024
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Jan 17, 2025

Study contacts

Rohit Shankar
Contact
rohit.shankar@plymouth.ac.uk
+44 (0) 1752 439831
Emily Stanyard
Contact
emily.stanyard@plymouth.ac.uk
+44 (0) 1752 439831
Lance Watkins
principal investigator · Swansea Bay University Health Board
Sarah Lennard
principal investigator · Cornwall Partnership NHS Foundation Trust
Heather Angus-Leppan
principal investigator · Royal Free London NHS Foundation Trust

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion